SavedAdd your journal

Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 4

Radyoaktif iyot tedavisi alan tiroid kanserli hastalarda tam kan sayımı değişiklikleri

The changes in complete blood count in thyroid cancer patients treated with radioactive iodine ablation therapy

Bircan SÖNMEZ
İsmail DOĞAN
Canan YAVRUOĞLU
Gamze ÇAN
MEHMET SÖNMEZ
Pages
269–274
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: RAI ablation therapy in thyroid cancer patients is a safe treatment modality without any serious or persistent hematological side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The aim of this study was to evaluate the effect of radioactive iodine (RAI) ablation therapy on the complete blood count (CBC) in thyroid cancer patients.
📊
Key Findings & Data:CBC results were available from the patients’ medical records at the time of ablation and at the 1st, 6th, and 12th months after RAI therapy.
💡
Conclusion & Impact:CONCLUSION: RAI ablation therapy in thyroid cancer patients is a safe treatment modality without any serious or persistent hematological side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The aim of this study was to evaluate the effect of radioactive iodine (RAI) ablation therapy on the complete blood count (CBC) in thyroid cancer patients. METHODS: One hundred sixty four patients undergoing RAI ablation therapy after total thyroidectomy were included. CBC results were available from the patients&#8217; medical records at the time of ablation and at the 1st, 6th, and 12th months after RAI therapy. RESULTS: Hemoglobin (Hb), white blood cell (WBC) and platelet (Plt) values were significantly lower than baseline at 1 month after treatment (p<0.0001). Hb and WBC values were increased at the 6th month and at the 1st year. Plt values increased at the 6th month but had decreased again at the 1st year. The values were usually in normal ranges except in the patients with low pretreatment Hb and WBC values. CONCLUSION: RAI ablation therapy in thyroid cancer patients is a safe treatment modality without any serious or persistent hematological side effects.

Özet

AMAÇ: Bu çalışmanın amacı total tiroidektomi sonrası artakalan tiroid dokusu için radyoaktif iyot (RAI) tedavisi alan tiroid kanserli hastalarda tam kan sayımındaki değişimleri değerlendimek. YÖNTEMLER: Total tiroidektomi sonrası RAI tedavisi almış 164 hasta değerlendirildi. Hastaların tedaviden önce ve tedavi sonrası 1. ay, 6. ay ve 12. ay hemoglobin (Hb), lökosit (WBC) ve trombosit (Plt) düzeyleri değerlendirildi. BULGULAR: RAI tedavisinden 1 ay sonra Hb, WBC ve Plt değerlerinde anlamlı bir azalma izlendi. Plt sayısı 6. ayda düzelirken 1. yılda tekrar azaldı. Buna karşılk Hb ve WBC değerlerinde ilk ayda gözlenen azalma 6. ay ve 1. yılda izlenmedi. Ancak izlenen bu değişiklikler tedavi öncesi değerleri düşük hastalar hariç normal sınırlar içindeydi. SONUÇ: Tiroid kanserli hastalarda RAI tedavisi ciddi bir hematolojik yan etkiye yol açmaksızın güvenilir bir tedavi yöntemidir.

🔖

Cite This Article

SÖNMEZ, B., DOĞAN, İ., YAVRUOĞLU, C., ÇAN, G., SÖNMEZ, M. (2010). Radyoaktif iyot tedavisi alan tiroid kanserli hastalarda tam kan sayımı değişiklikleri. Turkish Journal of Hematology, Cilt: 27 - Sayı: 4, 269–274. https://ajindex.com/articles/413176

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
  2. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009;19:1381-91
  3. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19:451-7
  4. Van Nostrand D, Freitas J. Side effects of I-131 for ablation and treatment of well-differentiated thyroid carcinoma. In: Wartofsky L, Van Nostrand D, editors. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press, 2006: 459-84
  5. Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Späth G, Biersack HJ. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503
  6. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451-6
  7. Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J HK Coll Radiol 2005;8:127-35
  8. Gutiérrez S, Carbonell E, Galofré P, Creus A, Marcos R. Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J Nucl Med 1999;26:1589-96
  9. Tofani A, Sciuto R, Cioffi RP, Pasqualoni R, Rea S, Festa A, Gandolfo GM, Arista MC, Maini CL. Radioiodineinduced changes in lymphocyte subsets in patients with differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:824-9
  10. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82
  11. Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic welldifferentiated thyroid carcinoma. J Nucl Med 1986;27:1519-27. 12. de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM. Bone marrow dosimetry